[Intrathecal application of antineoplastic agents (author's transl)].
D000630:Aminopterin / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001215:Asparaginase / Q000008:administration & dosage; D001375:Azaguanine / Q000008:administration & dosage; D001932:Brain Neoplasms / Q000188:drug therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004660:Encephalitis / Q000188:drug therapy; D005493:Folic Acid Antagonists / Q000008:administration & dosage; D006050:Gold Radioisotopes / Q000008:administration & dosage; D006801:Humans; D007278:Injections, Spinal; D007700:Kinetics; D007938:Leukemia / Q000188:drug therapy; D008159:Lumbar Vertebrae; D008727:Methotrexate / Q000008:administration & dosage; D013852:Thiotepa / Q000008:administration & dosage; D014748:Vinca Alkaloids / Q000008:administration & dosage
D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D006050:Gold Radioisotopes; D014748:Vinca Alkaloids; D003561:Cytarabine; D003520:Cyclophosphamide; D013852:Thiotepa; D001215:Asparaginase; D000630:Aminopterin; D001375:Azaguanine; D008727:Methotrexate
Die Intrathekale Gabe von Zytostatika.